Needham Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $23
Needham Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $23
Express News | Neumora Therapeutics Inc : Needham Initiates Coverage With Buy Rating; Target Price $23
Express News | Neumora Therapeutics Shares Are Trading Higher After Mizuho Initiated Coverage on the Stock With an Outperform Rating and Announced a $20 Price Target
Mizuho Securities Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $20
Neumora Therapeutics Analyst Ratings
Mizuho Securities Initiates Neumora Therapeutics at Outperform With $20 Price Target
Express News | Neumora Therapeutics Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $20
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Express News | Neumora Therapeutics Inc: Expects to Report Topline Data From Phase 1B Study in Second Half of 2025
Express News | Neumora Therapeutics Announces Initiation of Phase 1B Study of Nmra-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
BofA Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $22
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Express News | Neumora Therapeutics Inc : JP Morgan Cuts Target Price to $18 From $22
Express News | Neumora Therapeutics Initiates Phase 2 Study Of Navacaprant In Bipolar Depression, Expects To Report Topline Data In Second Half Of 2025
Express News | Neumora: Expects to Report Topline Data From Phase 2 Navacaprant Study in Second Half of 2025
Express News | Neumora Therapeutics Inc: Data From Koastal-1 Anticipated in Q4
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
No Data